Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Dynamic Chart
1 day-0.66%
3 months-0.59%
6 months+3.08%
Current year+97.79%
More quotes
Current year
29.73
Extreme 29.73
69.75
1 year
14.52
Extreme 14.52
69.75
3 years
11.81
Extreme 11.805
69.75
5 years
11.81
Extreme 11.805
146.30
10 years
11.81
Extreme 11.805
146.30
More quotes
Director TitleAgeSince
Chief Tech/Sci/R&D Officer - 21-07-31
Chief Tech/Sci/R&D Officer 50 22-09-30
Investor Relations Contact - 06-08-31
Manager TitleAgeSince
Director/Board Member 56 19-05-21
Director/Board Member - Jun. 05
Director/Board Member - Jun. 05
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.66%-.--% - - 2.82B
+0.52%-3.49%+8.08%-31.66%46.02B
-2.04%-3.37%+11.08%-7.66%44.31B
-1.87%-6.06%+22.50%+24.98%31.68B
+1.70%-5.81%+30.16%-27.17%29.63B
-0.75%-5.83%-32.66%-82.51%28.02B
-1.78%-6.07%+17.85%+15.31%25.05B
-1.25%-4.93%+54.74%+63.96%15.38B
-1.22%-3.38%-5.32%-44.27%11.34B
-3.36%-5.50%+25.35%+72.02%10.39B
Average -1.07%-4.62%+14.64%-1.89% 26.87B
Weighted average by Cap. -0.86%-4.45%+12.60%-10.37%
See all sector performances
2022 2023
Net sales 278M 308M 238M 264M
Net income -151M -167M -190M -210M
Net Debt - -
More financial data * Estimated data
Logo MorphoSys AG
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Employees
464
Calendar
More about the company

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW